# Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy

> **NCT00611039** · PHASE4 · COMPLETED · sponsor: **Germans Trias i Pujol Hospital** · enrollment: 30 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Darunavir 900mg + ritonavir 100 mg once a day
- **DRUG:** Darunavir 600mg + ritonavir 100mg twice day

## Key facts

- **NCT ID:** NCT00611039
- **Lead sponsor:** Germans Trias i Pujol Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00611039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00611039, "Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00611039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*